One of the key takeaways from the meeting, and from phase I of CHL UK, was that we tested and learned together for a whole year, but it’s now time to put our energy into what works.
In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.
Johnson & Johnson’s latest climate goals build on the legacy and achievement of our previous efforts, while accelerating action as part of the larger movement by the private sector, along with governments and civil society, to ramp up the ambition and implementation of climate goals during this new UN Decade of Action.
Johnson & Johnson (NYSE: JNJ) (the Company) recently announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies.
Porter Novelli and strategic partner Plan C joined together for a Climate Week virtual event on the business case for climate justice. The theme of the session was the role of racial justice and social equity in climate action. We heard from Jessica Appelgren of Impossible Foods; Celso White of Igniting Business Growth LLC; Bee Hui Yeh of the Power of We and Plan C and Erin Osher, Managing Director of Porter Novelli Seattle. Here, we’ve highlighted five key takeaways from the event:
We’re pleased to announce that based on interim results from our ongoing studies, the Janssen Pharmaceutical Companies of Johnson & Johnson are launching ENSEMBLE, a large-scale, multi-country Phase 3 trial of a single dose of our vaccine candidate.
Johnson & Johnson announced that we, alongside eight other companies working on investigational COVID-19 vaccines, are signing a #WeStandWithScience pledge committed to upholding the integrity of the scientific process as we work towards potential global regulatory filings and approvals of the first vaccines for COVID-19.
In Episode 5, Lisa Ling asks health experts for a pandemic status report, including the latest statistics on cases worldwide, the current thinking about coronavirus and its effects and what’s working to fight the disease—and what’s not.
After concluding the first year, more than 7200 children and adolescents in Mexico City and Chihuahua have benefited from the Essity and UNICEF partnership "Hygiene is our Rights"-program.
From epidemic masks introduced during the Spanish flu pandemic to work it's doing today on an investigational COVID-19 vaccine, learn how the company has been at the forefront of safeguarding global public health for well over a century.
Everyone’s financial journey is different. We make intentional efforts to meet the individual needs of clients and communities through a diverse range...
The SCS Kingfisher certification mark is showing up on an increasing number of products around the world. It differentiates companies that are making...
Corporate governance, risk management, operational integrity, and regulatory compliance are demanding challenges that companies face in today’s ever...
